JP2018502089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502089A5 JP2018502089A5 JP2017533856A JP2017533856A JP2018502089A5 JP 2018502089 A5 JP2018502089 A5 JP 2018502089A5 JP 2017533856 A JP2017533856 A JP 2017533856A JP 2017533856 A JP2017533856 A JP 2017533856A JP 2018502089 A5 JP2018502089 A5 JP 2018502089A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096020P | 2014-12-23 | 2014-12-23 | |
| US62/096,020 | 2014-12-23 | ||
| PCT/US2015/067459 WO2016106357A1 (en) | 2014-12-23 | 2015-12-22 | Combination of raf inhibitors and aurora kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502089A JP2018502089A (ja) | 2018-01-25 |
| JP2018502089A5 true JP2018502089A5 (enExample) | 2019-02-07 |
Family
ID=56151529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533856A Pending JP2018502089A (ja) | 2014-12-23 | 2015-12-22 | Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180263979A1 (enExample) |
| EP (1) | EP3236948A4 (enExample) |
| JP (1) | JP2018502089A (enExample) |
| CN (1) | CN107205933A (enExample) |
| CA (1) | CA2972076A1 (enExample) |
| WO (1) | WO2016106357A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11357776B2 (en) | 2016-10-28 | 2022-06-14 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof |
| WO2018204226A1 (en) | 2017-05-03 | 2018-11-08 | St. Jude Children's Research Hospital | Compositions and methods for prevention and treatment of hearing loss |
| JP7707166B2 (ja) * | 2019-11-27 | 2025-07-14 | デイ ワン バイオファーマシューティカルズ， インコーポレイテッド | Ｐａｎ－ｒａｆキナーゼインヒビターの固体分散物 |
| AU2021376286A1 (en) * | 2020-11-06 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Raf inhibitor for treating low grade glioma |
| CN116004567A (zh) * | 2022-12-07 | 2023-04-25 | 北京大学 | 极光激酶b基因k202突变及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003523940A (ja) * | 1999-05-11 | 2003-08-12 | オーソ−マクネイル ファーマシューティカル インコーポレイテッド | エリスロポエチン投与の薬物速度論的および薬力学的モデリング |
| EP1656146A4 (en) * | 2003-08-15 | 2009-04-15 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| CN101056632B (zh) * | 2004-11-09 | 2011-12-07 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| WO2006124863A2 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20130303519A1 (en) * | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| US20150126533A1 (en) * | 2012-03-30 | 2015-05-07 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| SG11201610534UA (en) * | 2014-06-16 | 2017-01-27 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
-
2015
- 2015-12-22 JP JP2017533856A patent/JP2018502089A/ja active Pending
- 2015-12-22 US US15/539,183 patent/US20180263979A1/en not_active Abandoned
- 2015-12-22 EP EP15874329.4A patent/EP3236948A4/en not_active Withdrawn
- 2015-12-22 WO PCT/US2015/067459 patent/WO2016106357A1/en not_active Ceased
- 2015-12-22 CN CN201580073520.8A patent/CN107205933A/zh active Pending
- 2015-12-22 CA CA2972076A patent/CA2972076A1/en not_active Abandoned